ReviewJournal of diabetes and metabolic disorders2026
Role of neddylation in diabetes metabolism: potential therapeutic target.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The study aimed to explore the role of neddylation in diabetes metabolism and its potential as a therapeutic target. Given the increasing global diabetes burden and limitations of current treatments, the research question was to determine how neddylation affects diabetes pathophysiology and if targeting it could offer new treatment strategies. Methods: The authors gathered data from a comprehensive review of existing research on neddylation in diabetes, including studies on insulin signaling, glucose and lipid metabolism, and related diseases. Experimental models, including diabetic mice and granulosa cells, and pharmacological interventions like MLN4924 were also thoroughly reviewed. By collating and evaluating these sources of information, the authors analyzed the influence of neddylation on diverse molecules and pathways implicated in diabetes. Results: Neddylation is involved in multiple aspects of diabetes. It affects insulin signaling by modifying insulin receptor substrate (IRS), inositol hexakisphosphate (IP6), phosphoenolpyruvate carboxykinase 1 (PCK1), and other molecules. Inhibiting neddylation with drugs like MLN4924 can reduce hepatic glucose generation, alleviate hyperglycemia, and improve metabolic phenotypes in mouse models. Neddylation is also associated with related diseases such as familial hyperkalemic hypertension, obesity - related metabolic disorders, and nonalcoholic steatohepatitis combined with type 2 diabetes. Conclusion: Neddylation plays a significant role in glucose metabolism regulation and diabetes pathogenesis. Targeting neddylation, especially with inhibitors like MLN4924, shows promise as a new therapeutic strategy for diabetes. Further research on neddylation in diabetes is needed to solidify its potential in treatment and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.